title: A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
abstract: Ninety-eight dogs with lymphoma treated with a 5-drug combination chemotherapy regimen (vincristine, L-asparaginase, cyclophosphamide, doxorubicin, prednisone [VELCAP-L]) were evaluated for pretreatment characteristics predictive for response and remission duration. The complete remission rate was 69%, with a median remission duration of 55 weeks. Dogs with advanced stage of disease, constitutional signs, dogs that were older, and dogs that were dyspneic were less likely to achieve remission. Once in remission, small dogs and dogs without pretreatment thrombocytopenia were likely to have longer remission duration. Toxicoses were frequent, but rarely fatal, and no predictitive factors were found for a dog developing toxicoses. VELCAP-L is an effective treatment for dogs in stage I-III lymphoma, particularly in young, small animals.
authors.affiliation: School of Veterinary Medicine, Vienna, Austria.
authors.forename: B I
authors.initials: BI
authors.lastname: Zemann
authors.forename: A S
authors.initials: AS
authors.lastname: Moore
authors.forename: W M
authors.initials: WM
authors.lastname: Rand
authors.forename: G
authors.initials: G
authors.lastname: Mason
authors.forename: D M
authors.initials: DM
authors.lastname: Ruslander
authors.forename: A E
authors.initials: AE
authors.lastname: Frimberger
authors.forename: C A
authors.initials: CA
authors.lastname: Wood
authors.forename: D A
authors.initials: DA
authors.lastname: L'Heureux
authors.forename: J
authors.initials: J
authors.lastname: Gliatto
authors.forename: S M
authors.initials: SM
authors.lastname: Cotter
mesh_terms: D000367:Age Factors; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging / Q000662:veterinary; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D012074:Remission Induction; D012737:Sex Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D011241:Prednisone